articleThe Lancet OncologySep 17, 2014Closed access

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

Kliniken Essen-Mitte · University of Duisburg-Essen · +21 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

2,459
total citations
FWCI
138.15
Percentile
100%
References
35
Citations per year

Authors

20

Topics & keywords

Keywords
  • Ramucirumab
  • Medicine
  • Placebo
  • Paclitaxel
  • Internal medicine
  • Clinical endpoint
  • Cancer
  • Gastroenterology
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding